文献速递血管炎

心血管药物、他汀与活检确诊巨细胞动脉炎:一项人群病例对照研究

Cardiovascular drug treatment, statins and biopsy-confirmed giant cell arteritis: a population-based case-control study.
PubMed 文献 · RMD Open · 2020-01-01

该研究基于瑞典人群开展病例对照研究,纳入574例活检确诊巨细胞动脉炎(GCA)患者和5740名匹配对照,评估心血管药物及他汀暴露与GCA风险的关联。结果显示他汀与GCA风险降低相关(OR 0.74,95%CI 0.61-0.90),其他研究药物未见明确关联。

要点

  • 他汀暴露与活检确诊GCA风险降低相关(OR 0.74,95%CI 0.61-0.90)。
  • 其他心血管药物(ACEI、ARB、β阻滞剂、钙拮抗剂、利尿剂等)与GCA无明确关联。
  • 新使用者分析中多数药物OR接近1,提示既往暴露分析需谨慎解读。

核心结论

  • 他汀可能与活检确诊的巨细胞动脉炎发病风险降低相关,其他研究的心血管药物未见明确关联。

研究设计与样本

  • 基于瑞典人群的病例对照研究,纳入574例活检确诊GCA患者和5740名按年龄、性别及居住区匹配的对照。
  • 通过瑞典处方药登记库识别2005年7月1日至诊断/索引日期前的心血管药物暴露,采用条件逻辑回归校正收入、教育水平和婚姻状况。

主要发现

  • GCA病例中71%在索引日期前至少有一次心血管药物配药记录,对照组为74%。
  • 多数目标药物与GCA关联的OR小于1,但仅新使用者分析中OR接近1。
  • 他汀与GCA风险降低一致相关,OR 0.74(95%CI 0.61至0.90)。

关键数值与推荐

  • 他汀与GCA关联的OR为0.74(95%CI 0.61至0.90)。
  • GCA病例平均诊断年龄75岁(SD 8),29%为男性;对照同样29%为男性。

临床怎么用

  • 对于需使用他汀的患者,本研究提示其可能与较低的GCA风险相关,但不构成开始他汀治疗的指征。
  • 其他心血管药物与GCA风险无明确关联,临床不应因GCA风险而改变这些药物的使用。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether exposure to cardiovascular medications and statins is associated with increased risk of giant cell arteritis (GCA). DESIGN: The population-based case-control study comprised a cohort of patients with biopsy-confirmed GCA linked to the Swedish Prescribed Drug Register to identify all exposure to drugs prior to diagnosis of GCA. Ten controls per GCA case, matched for age, sex and residential area, were included. Using corresponding Anatomical Therapeutic Chemical codes, ACE inhibitors, angiotensin II receptor blockers, beta-blocking agents, calcium antagonists, diuretics, statins and cardiac therapy drugs were investigated from July 1, 2005 to the diagnosis/index date. A conditional logistic regression model was fitted adjusted for income, education level and marital status. We repeated the analyses including only new drug users excluding those with any prescription during the year from July 1, 2005 to July 1, 2006. RESULTS: 574 cases (29% men) of diagnosed GCA and 5740 controls (29% men) were included. The mean age at diagnosis is 75 years (SD 8). Of the GCA cases, 71% had at least one dispensation of a cardiovascular drug prior to the index date, compared to 74% of controls. The ORs for the association of target drug exposure with GCA were <1 for most drugs, but close to 1 in the analysis of new users. Statins were consistently associated with lower risk of GCA, OR 0.74 (95% CI 0.61 to 0.90). CONCLUSION: Statins may be associated with lower risk of incident biopsy-confirmed GCA. No association was evident for other studied drugs.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Turkiewicz A, Stamatis P, Mohammad AJ, et al. Cardiovascular drug treatment, statins and biopsy-confirmed giant cell arteritis: a population-based case-control study. RMD Open. 2020. PMID: 32792416. doi:10.1136/rmdopen-2020-001285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。